Entrada Therapeutics, Inc.
TRDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $93 | $72 | $68 | $101 |
| Short-Term Investments | $234 | $282 | $315 | $319 |
| Receivables | $3 | $1 | $2 | $4 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $14 | $19 | $16 |
| Total Curr. Assets | $338 | $369 | $403 | $440 |
| Property Plant & Equip (Net) | $71 | $75 | $79 | $82 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $4 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $4 | $4 | $4 |
| Total NC Assets | $75 | $80 | $83 | $86 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $413 | $449 | $486 | $526 |
| Liabilities | – | – | – | – |
| Payables | $3 | $2 | $2 | $4 |
| Short-Term Debt | $4 | $5 | $7 | $8 |
| Tax Payable | $0 | $0 | $1 | $1 |
| Deferred Revenue | $0 | $1 | $1 | $14 |
| Other Curr. Liab. | $16 | $12 | $8 | $13 |
| Total Curr. Liab. | $24 | $20 | $18 | $39 |
| LT Debt | $48 | $49 | $50 | $52 |
| Deferred Rev, NC | $0 | $0 | $0 | $7 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $48 | $49 | $51 | $58 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $48 | $55 | $57 | $59 |
| Total Liabilities | $72 | $69 | $69 | $98 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$234 | -$190 | -$147 | -$129 |
| AOCI | $1 | $0 | $0 | -$0 |
| Other Equity | $574 | $569 | $564 | $558 |
| Total Equity | $341 | $380 | $417 | $429 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $413 | $449 | $486 | $526 |
| Net Debt | -$41 | -$18 | -$11 | -$42 |